cytochrome P450 family 1 subfamily D member 1, pseudogeneGenealiases: CYP1A8P · CYP1D1
Q-omics provides the consensus-scored CYP1D1P profile across patient tissues and cancer cell-line models. CYP1D1P expression is associated with patient survival in 13 of 34 cancer types, with the highest sampling consensus in KIRC. Among the 18 cancer types available for tumor–normal comparison, CYP1D1P is differentially expressed in 5, with the highest sampling consensus in KIRC. Additionally, CYP1D1P RNA expression shows 8,840 significant protein co-abundance associations, with the highest sampling consensus in CCRCC. Together, these results highlight KIRC, and CCRCC as cancer lineages where CYP1D1P shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for CYP1D1P — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes CYP1D1P survival associations across molecular data types. CYP1D1P RNA expression shows survival associations in the most cancer types (13). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible CYP1D1P RNA expression–survival associations across cancer types. High CYP1D1P expression shows unfavorable associations in BLCA, CESC, UCEC, UCS and LUAD, but favorable associations in KIRC. The KIRC Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify KIRC as the clearest survival context for CYP1D1P RNA expression.
This table summarizes CYP1D1P tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 5. The strongest signals are observed in KIRC for RNA.
This table ranks reproducible tumor–normal expression differences for CYP1D1P. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. CYP1D1P shows lower tumor expression in KICH, PAAD and BRCA and higher tumor expression in KIRC and LIHC. The KIRC box plot shows higher CYP1D1P RNA expression in tumor versus normal tissue (log2 FC = +0.195, t-test p < 0.001).
This table shows molecular features associated with CYP1D1P in patient tissues and cancer cell lines. In patient samples, CYP1D1P shows the broadest associations at the RNA and protein expression levels, with CCRCC recurring as the lineage with the largest associated feature set.
